Evidence map›Paper›PMID 41222708›Full record

ReviewJournal of neural transmission (Vienna, Austria : 1996)2025

Pharmacogenetics in advanced Parkinson's disease.

Jaime Kulisevsky, Pedro García-Ruíz, Tiago Fleming Outeiro, Tanya Gurevich, Péter Klivènyi, Teus Van Laar, Ivan Milanov, Walter Pirker, Bogdan O Popescu, Mathias Toft and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neural transmission (Vienna, Austria : 1996), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jaime KulisevskyMedicine Department, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. jkulisevsky@santpau.cat.ORCID 0000-0003-4870-1431
Pedro García-RuízMovement Disorders Unit, Department of Neurology, Fundación Jimenez Diaz, Madrid, Spain.
Tiago Fleming OuteiroDepartment of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, Göttingen, Germany.
Tanya GurevichMovement Disorders Unit, Neurological Institute, Gray Faculty of Medical and Health Science & Sagol School of Neuroscience, Tel Aviv Medical Center, Tel Aviv University, Tel Aviv, Israel.
Péter KlivènyiDepartment of Neurology, University of Szeged, Szeged, Hungary.
Teus Van LaarDepartment of Neurology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713GZ, the Netherlands.
Ivan MilanovUniversity Neurological and Psychiatric Hospital "St. Naum", Medical University Sofia, Sofia, Bulgaria.
Walter PirkerDepartment of Neurology, Klinik Ottakring, Vienna, Austria.
Bogdan O PopescuDepartment of Clinical Neurosciences, 'Carol Davila' University of Medicine and Pharmacy Bucharest, Bucharest, Romania.
Mathias ToftDepartment of Neurology, Oslo University Hospital, Oslo, Norway.
József Attila SzászGE Palade University of Medicine, Pharmacy, Science and Technology of Târgu , Târgu Mureș, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder with a wide variety of symptoms and evolution. In addition, the response to antiparkinsonian medication is not predictable, especially for those patients with advanced PD. Pharmacogenetics and pharmacogenomics may help to decide the best available treatment based on the genetic background of the patients. This approach has been already used in Oncology leading to personalized pharmacology. In this article, we review and comment the updated information regarding pharmacogenetics and pharmacogenomics applied to PD.

Indexed as

Antiparkinson AgentsParkinson DiseasePharmacogeneticsHumansAntiparkinson AgentsParkinson´s diseasePharmacogeneticsPharmacogenomics

Identifiers

PMID41222708

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.